ASND Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of --. Ascendis Pharma AS's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of --.

Ascendis Pharma AS has a consensus price target of $189.82, signalling upside risk potential of 37.87%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 86.87%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Ascendis Pharma AS, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.675, which suggesting that the stock is 32.529% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $63.6M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Ascendis Pharma AS's net income of -$109.1M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.33x versus 3.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Evaxion Biotech AS has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of -64.14%. Ascendis Pharma AS's return on equity of -- beat Evaxion Biotech AS's return on equity of --.

Ascendis Pharma AS has a consensus price target of $189.82, signalling upside risk potential of 37.87%. On the other hand Evaxion Biotech AS has an analysts' consensus of -- which suggests that it could grow by 1192.23%. Given that Evaxion Biotech AS has higher upside potential than Ascendis Pharma AS, analysts believe Evaxion Biotech AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.675, which suggesting that the stock is 32.529% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $63.6M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Ascendis Pharma AS's net income of -$109.1M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.33x versus 1.24x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of 38.28%. Ascendis Pharma AS's return on equity of -- beat Novo Nordisk AS's return on equity of 88.95%.

Ascendis Pharma AS has a consensus price target of $189.82, signalling upside risk potential of 37.87%. On the other hand Novo Nordisk AS has an analysts' consensus of $122.21 which suggests that it could grow by 39.88%. Given that Novo Nordisk AS has higher upside potential than Ascendis Pharma AS, analysts believe Novo Nordisk AS is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.675, which suggesting that the stock is 32.529% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.66% to investors and pays a quarterly dividend of $0.52 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 37.96% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ascendis Pharma AS quarterly revenues are $63.6M, which are smaller than Novo Nordisk AS quarterly revenues of $10.5B. Ascendis Pharma AS's net income of -$109.1M is lower than Novo Nordisk AS's net income of $4B. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 28.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.33x versus 9.92x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

Trinity Biotech PLC has a net margin of -171.53% compared to Ascendis Pharma AS's net margin of -31.41%. Ascendis Pharma AS's return on equity of -- beat Trinity Biotech PLC's return on equity of --.

Ascendis Pharma AS has a consensus price target of $189.82, signalling upside risk potential of 37.87%. On the other hand Trinity Biotech PLC has an analysts' consensus of -- which suggests that it could grow by 1712.69%. Given that Trinity Biotech PLC has higher upside potential than Ascendis Pharma AS, analysts believe Trinity Biotech PLC is more attractive than Ascendis Pharma AS.

Ascendis Pharma AS has a beta of 0.675, which suggesting that the stock is 32.529% less volatile than S&P 500. In comparison Trinity Biotech PLC has a beta of 0.969, suggesting its less volatile than the S&P 500 by 3.133%.

Ascendis Pharma AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Trinity Biotech PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ascendis Pharma AS pays -- of its earnings as a dividend. Trinity Biotech PLC pays out -- of its earnings as a dividend.

Ascendis Pharma AS quarterly revenues are $63.6M, which are larger than Trinity Biotech PLC quarterly revenues of $15.2M. Ascendis Pharma AS's net income of -$109.1M is lower than Trinity Biotech PLC's net income of -$4.8M. Notably, Ascendis Pharma AS's price-to-earnings ratio is -- while Trinity Biotech PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ascendis Pharma AS is 22.33x versus 0.15x for Trinity Biotech PLC. Usually stocks with elevated PS ratios are considered overvalued.